Allogene Therapeutics Inc. has raised $744m to date, including its $324m initial public offering on Oct. 10, and with its coffers full of cash Chief Financial Officer Eric Schmidt tells Scrip that the allogeneic chimeric antigen receptor T-cell (CAR-T) therapy developer is ready to "go full throttle."
[Sidebar#SC100692]






